| When: Thursday, 11/4/2021, 3:00 pm - 4:30 pm |
| Credits: 1.5 CME_Physicians Credits |
| Credits: 1.5 CME_OtherProfessions Credits |
|
| Description: Obesity is a heterogeneous disease. Sustained weight losswith current treatment paradigms remains a challenge in clinical practice since anti-obesity medications have a highly variable weight loss response rate. This symposium will focus on actionable predictors of response to obesity treatments, focusing on lifestyle and pharmacotherapeutic options in both adolescents and adults. Learn how to individualize your prescribing patterns to best care for patients with obesity.
Dr. Yanovski would like the audience to be aware that he may discuss the off-label use of setmelanotide for Bardet-Biedl Syndrome and other conditions, diazoxide choline controlled-release tablets, and leptin during this presentation.
This session was jointly produced by The Obesity Society (TOS) and Preventive Cardiovascular Nurses Association (PCNA).
|
| Delivery Mechanism: Broadcast |
| Keyword: Methodologies: Precision Obesity/Precision Nutrition; Treatment: Clinical Practice; Treatment: Individual Variability |
Track: Sub-track: Obesity Medicine Exam Prep; Track 3: Interventional and Clinical Studies; Track 5: Clinical/Professional Practice
|
|
Speakers:
 | Jaime P. Almandoz, MD, MBA, FTOS | Session Chair | |  | Rena R. Wing, PhD | Lifestyle Predictors of Weight Loss | 3:00 pm - 3:20 pm |  | Caroline M. Apovian, MD | Pharmacogenomic and Phenotype-guided Pharmacotherapy for Adult Obesity | 3:20 pm - 3:40 pm |  | Jack A. Yanovski, MD, PhD | Pharmacogenomic and Phenotype-guided Pharmacotherapy for Child/Adolescent Obesity | 3:40 pm - 4:00 pm | | Jaime P. Almandoz, MD, MBA, FTOS | Moderate Panel Q&A | 4:00 pm - 4:30 pm | | Rena R. Wing, PhD | Panel Q&A | 4:00 pm - 4:30 pm | | Jack A. Yanovski, MD, PhD | Panel Q&A | 4:00 pm - 4:30 pm | | Caroline M. Apovian, MD | Panel Q&A | 4:00 pm - 4:30 pm |
|
|
| Learning Objectives: |
| 1. Apply the latest recommendations for evaluation and treatment; tailor intervention strategies based on patient characteristics such as age or metabolic or behavioral phenotype; understand the differences between weight loss and weight loss maintenance. |
| 2. Understand the evidence-based science regarding neuroendocrine, environmental, endocrine, microbiota and/or cognitive behavioral mechanisms regulating energy balance and body weight. Apply that knowledge to develop and implement treatment options for adults and pediatric patients with overweight, obesity or obesity-related co-morbidities. |
| 3. Implement appropriate strategies for diagnosing adolescent and pediatric obesity, evaluate current treatment options and emerging therapeutics and provide care and treatment to adolescent and pediatric patients accordingly. Teach evidence-based strategies for obesity prevention in the pediatric and adolescent population. |
|
|